E. V. Krivova

E. V. Krivova

Auto-generated profile, based on publicly available information

E. V. Krivova

Central State Medical Academy of Department of Presidential Affairs

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2026 in Russian Journal of Clinical Dermatology and Venereology
Verified
Journal Article
Closed access
TBT.S. Belysheva
T.S. Belysheva
EKE.V. Krivova
E.V. Krivova
NBN.P. Baranova
N.P. Baranova
MNM.S. Neznakhina
M.S. Neznakhina
ISI.L. Shlivko
I.L. Shlivko
SVS.R. Varfolomeeva
S.R. Varfolomeeva
The success of treatment of childhood malignant tumors is related to the improvement of antitumor drug treatment protocols. However, these agents cause toxicity, most often — skin toxic reactions. Prevention and treatment of dermal toxicity are evolving with emergence of new knowledge about the mechanisms of action of antitumor drugs and understanding of the pathogenesis of drug-induced cutaneous reactions. Objective. To prove the efficacy and safety of the use of background therapy and moisturizers in children receiving systemic drug antitumor treatment. Material and methods. A multicenter prospective observational study, which included 60 patients, was implemented in the L.A. Durnova Research Institute of Children’s Oncology and Hematology of the N.N. Blokhin National Medical Research Center of Oncology for 3 years (October 2022 — October 2025). Patients were divided into 2 groups: receiving background therapy for skin toxic reactions (the 1st group) and combination of background therapy with moisturizing agents (the 2nd group). Median age was 8 years in the 1st group, 9 years in the 2nd. Gender distribution in the 1st group — 43.5% were boys and 56.5% were girls; in the 2nd group — 54.5% and 45.5%, respectively. Results. Statistically significant differences were not found (p=0.16) when comparing functional indicators of the skin in the 1st and 2nd groups, but there was a tendency to a more pronounced improvement in the dynamics of the indicators (reduction of itching, pain sensation and skin dryness) in the 2nd group. Patients of the 2nd group reported a faster regression of skin toxic reactions and a high level of comfort. Conclusion. Prevention and timely monitoring of skin toxic reactions is an integral part of the comprehensive management of patients receiving antitumor therapy. The use of background therapy and moisturizers depending on the severity, as well as the multidisciplinary interaction of oncologist and dermatologist, allow to control the skin toxicity without the need to interrupt vital antitumor treatment.

27 December 2025 in Russian Journal of Clinical Dermatology and Venereology
Verified
Journal Article
Closed access
TBT.S. Belysheva
T.S. Belysheva
EKE.V. Krivova
E.V. Krivova
NBN.P. Baranova
N.P. Baranova
MNM.S. Neznakhina
M.S. Neznakhina
ISI.L. Shlivko
I.L. Shlivko
SVS.R. Varfolomeeva
S.R. Varfolomeeva
Current protocols of anti-cancer therapy in pediatric oncology demonstrate high efficacy, but their application is often accompanied by development of toxic effects. Skin toxic reactions toxicity occupies one of the leading places in the structure of adverse events of drug treatment, significantly affecting the quality of life of patients and limiting the opportunity to carry out anti-cancer therapy at the scheduled doses and time periods. Skin reactions can be caused by a wide range of anti-cancer drugs, including cytostatics (paclitaxel, methotrexate, cytarabine, doxorubicin), targeted (crizotinib, epidermal growth factor receptor (EGFR) inhibitors) and immunotargeted (dinutuximab, etc.) drugs. Acne-like eruptions, hand-foot syndrome, maculopapular rash, alopecia, itching, xerosis as well as rare but potentially life-threatening bullous dermatoses are the most common manifestations. The article presents data on the spectrum and incidence of adverse dermatological reactions in children receiving modern anti-cancer drugs and considers the role of concomitant therapy in the correction of skin toxic reactions. Timely application of accompanying treatment agents allows to minimize skin damage, accelerate restoration of the skin barrier and increase adherence to anti-cancer treatment. Special attention is given to the preventive measures and treatment of dermatological reactions, which helps to prevent their progression and reduce the risk of forced discontinuation or modification of the background therapy.

10 September 2025 in Russian Journal of Clinical Dermatology and Venereology
Verified
Journal Article
Closed access
TBT.S. Belysheva
T.S. Belysheva
EKE.V. Krivova
E.V. Krivova
VGV.A. Grigorenko
V.A. Grigorenko
NBN.P. Baranova
N.P. Baranova
ERE.S. Rannev
E.S. Rannev
SVS.R. Varfolomeeva
S.R. Varfolomeeva
Radiation therapy, being an integral part of malignant neoplasms treatment in children, is unfortunately inevitably accompanied by a high frequency of adverse dermatological reactions. Development of radiodermatitis — from erythema and dryness to oozing lesion, painfulness and ulcerations — is a considerable clinical problem, significantly deteriorates the quality of life of young patients and creates the risk of infectious complications, that could potentially lead to interruptions in life-saving treatment. Critically important is that currently there are almost no randomized controlled studies in the pediatric population specifically devoted to systematic assessment of profile, severity and optimal management of dermatological toxicity caused by radiation therapy. This article focuses on the urgent need and crucial significance of comprehensive supportive skin therapy during and after radiation. Such care includes regular and targeted use of special dermatoprotective products. Moisturizing creams and ointments are designed to combat dryness, desquamation and maintain the integrity of the hydrolipid barrier. Barrier agents (often based on zinc, silicone or special polymers) create a protective film that minimizes friction, mechanical damage and contact with irritants as well as promote healing. The main objectives of this strategy are effective management of clinical manifestations of acute radiodermatitis, maximum possible prevention and minimization of severe skin lesions, as well as significant acceleration of their recovery and re-epithelization processes in the post-radiation period. The obtained results and collated recommendations are of significant practical interest to a wide range of specialists — dermatologists, pediatric oncologists, pediatricians and radiotherapists, who directly comprehensively treat children with malignant tumors, undergoing radiation therapy, and strive to optimize their treatment tolerability and quality of life.

11 November 2025 in Medical alphabet
Verified
Journal Article
Open access
PDF file
TBT. S. Belysheva
T. S. Belysheva
VSVera Semenova
Vera Semenova
ESE. V. Sharapova
E. V. Sharapova
EKE. V. Krivova
E. V. Krivova
EZEkaterina Zelenova
Ekaterina Zelenova
TNTatiana Nasedkina
Tatiana Nasedkina
Gorlin‑Goltz syndrome (GGS) is a rare autosomal dominant disorder caused by mutations in the PTCH1 and SUFU genes, key components of the Sonic Hedgehog signaling pathway. GGS is characterized by a high risk of developing tumors, primarily basal cell carcinoma (BCC) and medulloblastoma. The article presents a clinical case of an 11‑year‑old patient with PTCH1‑associated GGS, who was diagnosed with medulloblastoma at the age of 3 years, and by the age of 6 years, multiple basal cell skin cancer manifested. The clinical case highlights the importance of early diagnosis, timely molecular genetic testing and interdisciplinary monitoring to improve the prognosis and quality of life of patients with this syndrome.